A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind placebo-controlled safety study conducted in
2 study cohorts. In Cohort 1, subjects with Alzheimer's disease (n=250) will receive Dimebon
20 mg or placebo TID for 26 weeks. In Cohort 2 AD subjects (n=500) will be treated with
Dimebon 20 mg or placebo TID for 12 weeks After completion of the randomized portion of the
study, subjects in both Cohorts will have the opportunity to enroll in a Dimebon open label
extension study.